Phase 2 N=111 A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes
Type 2 Diabetes
Primary: Change From Baseline in Haemoglobin A1c (HbA1c) — 0.2; -1.7; -2.0; -1.8 Percentage of HbA1C — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=90 Blu Light for Ulcers Reduction
Leg Ulcers Venous · Dehiscence, Surgical Wound
Primary: Size of Wound Remaining Compared to Initial Wound Size — 42.58; 53.78 percentage of the remaining area
Phase 3 N=498 Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab
Crohn Disease
Primary: Percentage of Participants With Endoscopic Response at Week 48 — 37.9; 29.9 Percentage of Participants — p== 0.0871
N/A N=15 The S.M.A.R.T. Project: Stress Management and Resilience Training for Teens
Depression Mild · Resilience, Psychological · Adolescent Behavior
Primary: Time to Incident Depression — 36; 18.86 weeks — p=0.02
N/A N=10 Detection and Quant of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using Positron Emission Tomography/Computed Tomography (PET/CT)
Lymphoma
Primary: Percentage Change in Maximum Lesional FDG Uptake From 60 to 180 Minutes After FDG Administration — 36.2; 32 percentage of change in maximum SUV
Phase 2 N=36 Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases
Breast Cancer · Brain Tumor - Metastatic
Primary: CNS Objective Response Rate (ORR) — 5; 14; 0 percentage of participants
N/A N=45 Usability of the Software MacuFix for the Categorization of Metamorphopsia
Vision Disorders
Primary: Score of System Usability Scale (SUS) Questionnaire — 76.7 score on a scale
N/A N=52 Treatment of Unresectable Colorectal Metastases by Radiofrequency Ablation Combined or Not With Resection, With or Without Neoadjuvant Chemotherapy.
Colorectal Cancer
Primary: Complete Hepatic Response Rate at 3 Months — 79 percentage of participants
Phase 3 N=3,730 EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)
Heart Failure
Primary: Time to the First Event of Adjudicated Cardiovascular (CV) Death or Adjudicated Hospitalisation for Heart Failure (HHF) — 21.00; 15.77 Patients with events/ 100 pt-yrs…
N/A N=60 A Comparison of Two Urinary Catheters of Different Lengths for Female Use, in Intermittent Catheterization
Catheterization
Primary: Bladder Scan Measurements of Residual Urine Volume — 32.74; 34.78 Residual volume in mL — p=0.8762
N/A N=262 Acinetobacter Baumannii-related Osteomyelitis: Clinical and Epidemiological Characterization
Osteomyelitis
Primary: Description of the Clinical and Epidemiological Profile of Patients With Infection — 92; 26; 25; 21 Participants
Phase 2 N=265 AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)
Lupus Nephritis
Primary: Number of Subjects Achieving Complete Renal Remission at 24 Weeks — 29; 24; 17; 60 Participants — p=0.045
N/A N=114 Pharmacogenomics of Thiazolidinediones
Type 2 Diabetes
Primary: Change in Insulin Resistance — -0.83 HOMA-IR index is unitless by definition — p=<0.0000001
Phase 1 N=50 Pharmacokinetics and Safety Study of Omecamtiv Mecarbil in Healthy Japanese Adults
Healthy Volunteer
Primary: Dosing Period 1: Maximum Observed Plasma Concentration (Cmax) of Omecamtiv Mecarbil After First and Last Dose in Period 1 — 77.4; 79.5; 256; 259 ng/mL
Phase 3 N=65 Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia
Homozygous Familial Hypercholesterolemia
Primary: Percent Change in Calculated Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 24 (Intent-to-Treat [ITT] Estimand) — 1.9; -47.1 Percent Change — p=< 0.0001